UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD

- - - - - - - - - - - +

MYLAN PHARMACEUTICALS, INC.,

Petitioner,

vs.

YEDA RESEARCH AND DEVELOPMENT
CO., LTD.,

Patent Owner.

- - - - - - - - - - - +

Case IPR2015-00643 (8,232,250)

Case IPR2015-00644 (8,399,413)

Case IPR2015-00830 (8,969,302)

(And case numbers corresponding

to the joined Amneal IPRs)

Deposition of HENRY G. GRABOWSKI, Ph.D., taken on behalf of Amneal Pharmaceuticals at the offices of Duane Morris LLP, 100 High Street, Suite 2400, Boston, Massachusetts 02110, beginning at 10:10 a.m. on February 10, 2016 before Dana Welch, CSR, RPR, CRR, CRC and Notary Public for the Commonwealth of Massachusetts.





| | | 3 |
|----|--|---|
| 1 | APPEARANCES (continued) | |
| 2 | ON BEHALF OF AMNEAL PHARMACEUTICALS: | |
| 3 | VINCENT L. CAPUANO, Ph.D., ESQUIRE | |
| 4 | Duane Morris LLP | |
| 5 | 100 High Street, Suite 2400 | |
| 6 | Boston, MA 02110-1724 | |
| 7 | (857) 488-4250 | |
| 8 | vcapuano@duanemorris.com | |
| 9 | | |
| 10 | Also present: Lori Wolfe, Teva Pharmaceuticals | |
| 11 | | |
| 12 | | |
| 13 | | |
| 14 | | |
| 15 | | |
| 16 | | |
| 17 | | |
| 18 | | |
| 19 | | |
| 20 | | |
| 21 | | |
| 22 | | |
| 23 | | |
| 24 | | |
| 25 | | |
| | | |



| | | 4 |
|----|--|-------|
| 1 | INDEX | |
| 2 | WITNESS: | |
| 3 | HENRY G. GRABOWSKI, Ph.D. | |
| 4 | | |
| 5 | EXAMINATION: | PAGE: |
| 6 | BY MR CAPUANO | 7 |
| 7 | EXHIBITS MARKED: | |
| 8 | NO. DESCRIPTION | PAGE: |
| 9 | None marked | |
| 10 | | |
| 11 | EXHIBITS PREVIOUSLY MARKED: | |
| 12 | NO. DESCRIPTION | PAGE |
| 13 | Yeda Exhibit 2105, List of Testimony of | 15 |
| 14 | Henry G. Grabowski | |
| 15 | Yeda Exhibit 2107, Approval Timeline | 55 |
| 16 | Multiple Sclerosis Drugs | |
| 17 | Yeda Exhibit 2108, Copaxone 40 mg/mL | 20 |
| 18 | Wholesale Dollar Sales Q1 2014 - Q3 2015 | |
| 19 | Yeda Exhibit 2109, Copaxone 40 mg/mL | 29 |
| 20 | Extended Units Q1 2014 - Q3 2015 | |
| 21 | Yeda Exhibit 2110, Copaxone 40 mg/mL Total | 35 |
| 22 | Prescriptions Q1 2014 - Q3 2015 | |
| 23 | Yeda Exhibit 2111, Copaxone 40 mg/mL New | 36 |
| 24 | Prescriptions Q1 2014 - Q3 2015 | |
| 25 | index continues | |
| | | ļ |



| | | | 5 |
|----|--|------|---|
| 1 | INDEX (continued) | | |
| 2 | EXHIBITS PREVIOUSLY MARKED | | |
| 3 | NO. DESCRIPTION | PAGE | |
| 4 | Yeda Exhibit 2112, Multiple Sclerosis | 42 | |
| 5 | Drugs Share of Wholesale Dollar Sales Q4 | | |
| 6 | 2009 - Q3 2015 | | |
| 7 | Yeda Exhibit 2113 Multiple Sclerosis Drugs | 45 | |
| 8 | Share of Total Prescriptions Q4 2009 - Q3 | | |
| 9 | 2015 | | |
| 10 | Yeda Exhibit 2115, Rationale for | 60 | |
| 11 | Requesting Copaxone | | |
| 12 | Yeda Exhibit 2117, Rationale for | 65 | |
| 13 | Discussing 20 mg and 40 mg for First Line | | |
| 14 | Patients | | |
| 15 | Yeda Exhibit 2118, Perceptions of Copaxone | 80 | |
| 16 | 40 mg vs. 20 mg | | |
| 17 | Yeda Exhibit 2119, Perceptions of Copaxone | 71 | |
| 18 | 40 mg compared to Daily Generic GA | | |
| 19 | Yeda Exhibit 2120, Copaxone Total | 54 | |
| 20 | Prescriptions Q4 2009 - Q3 2015 | | |
| 21 | Yeda Exhibit 2121, Copaxone 20 mg/mL, | 68 | |
| 22 | Copaxone 40 mg/mL and Glatopa Net | | |
| 23 | Prescriptions Flow 10/26/12 - 10/9/15 | | |
| 24 | Yeda Exhibit 2122, Total Promotional | 91 | |
| 25 | Spending to Sales Ratio | | |
| | | | |



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

